The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms by Fulcher, Luke et al.
                                                              
University of Dundee
The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms
Fulcher, Luke; Bozatzi, Polyxeni; Tachie-Menson, Theresa; Wu, Kevin; Cummins, Timothy D.;
Bufton, Joshua C.; Pinkas, Daniel M.; Dunbar, Karen; Shrestha, Sabin; Wood, Nicola;
Weidlich, Simone; Macartney, Thomas; Varghese, Joby; Gourlay, Robert; Campbell, David;
Dingwell, Kevin S.; Smith, James C.; Bullock, Alex N.; Sapkota, Gopal
Published in:
Science Signaling
DOI:
10.1126/scisignal.aao2341
Publication date:
2018
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Fulcher, L., Bozatzi, P., Tachie-Menson, T., Wu, K., Cummins, T. D., Bufton, J. C., ... Sapkota, G. (2018). The
DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms. Science Signaling, 11(531),
[eaao2341]. https://doi.org/10.1126/scisignal.aao2341
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
The DUF1669 domain of FAM83 family proteins anchor Casein Kinase 1 isoforms 
Luke J Fulcher1, Polyxeni Bozatzi1, Theresa Tachie-Menson1, Kevin Z L Wu1, Timothy D 
Cummins1, Joshua C Bufton3, Daniel M Pinkas3, Karen Dunbar1, Sabin Shrestha1, Nicola T 
Wood1, Simone Weidlich1, Thomas J Macartney1, Joby Varghese1, Robert Gourlay1, David G 
Campbell1, Kevin S Dingwell2, James C Smith2, Alex N Bullock3 and Gopal P Sapkota1* 
1Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, Dundee, Scotland, 
UK, 2The Francis Crick Institute, London, UK, 3Structural Genomics Consortium, University of 
Oxford, Oxford, UK. 
*Corresponding Author. Email: g.sapkota@dundee.ac.uk
Abstract 
The casein kinase 1 (CK1) family of serine-threonine protein kinases are implicated in the 
regulation of many cellular processes, including the cell cycle, circadian rhythms, and Wnt and 
Hedgehog signalling. It is therefore critically important to understand how their activity is 
controlled in cells. Because these kinases exhibit constitutive activity in biochemical assays, it is 
likely that their activity in cells is controlled by subcellular localization, interactions with inhibitory 
proteins, targeted degradation, or combinations of these mechanisms. We identified members 
of the FAM83 family of proteins as partners of CK1 in cells. All eight members of the FAM83 
family (FAM83A–H) interacted with the a and a-like isoforms of CK1; FAM83A, -B, -E, and -H 
also interacted with the d and e isoforms of CK1. We detected no interaction between any 
FAM83 member with the related CK1γ1, -2 and -3 isoforms. Each FAM83 protein exhibited a 
distinct pattern of subcellular distribution and colocalized with the CK1 isoform(s) to which it 
bound. The interaction of FAM83 proteins with CK1 isoforms was mediated by the conserved 
domain of unknown function 1669 (DUF1669) that characterises the FAM83 family. Mutations in 
FAM83 proteins that prevented them from binding to CK1 interfered with the proper subcellular 
localization of both the FAM83 proteins and their CK1 binding partners  and interfered with the 
cellular functions of both families of proteins. Based on its function, we propose that DUF1669 
be renamed the polypeptide anchor of CK1 (PACK1) domain. 
This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not 
for redistribution. The definitive version was published in Science Signaling on 22/05/2018, vol. 11, DOI: 
10.1126/scisignal.aao2341
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Introduction 
The eight members of the FAM83 family of proteins are conserved in vertebrates but are poorly 
characterised. They share a conserved N-terminal DUF1669 (domain of unknown function 
1669) domain of ~300 amino acids, but each member possesses unique C-terminus of variable 
length (1, 2). The amino acid sequences of the FAM83 family members offer very few clues to 
their functions. The DUF1669 domain contains a putative phospholipase D–like (PLD-like) 
catalytic motif, which is characterized by the presence of an HxKxxxxD (HKD) sequence motif. 
Typically, two such motifs exist within each PLD protein, with the two HKD motifs coming 
together to form the catalytic core of the enzyme (3). FAM83 proteins, on the other hand, have 
only one HKD motif, and the histidine residue within the motif is absent from all but FAM83D 
(also known as CHICA) (fig. S1). No PLD activity has yet been demonstrated for any FAM83 
member (4). Recent studies have implicated FAM83A and FAM83B in oncogenesis and 
resistance to tyrosine kinase inhibitors (4-6). FAM83D has been reported to localize to the 
mitotic spindle and interact with the chromokinesin kinesin family member 22 (KIF22, also called 
Kid), the microtubule-binding protein hyaluronan-mediated motility receptor (HMMR), and the 
light chain of the motor protein dynein (DYNLL1) to correctly orient the metaphase plate in 
mitosis (7, 8). FAM83G, also known as PAWS1 [protein associated with suppressor of mothers 
against decapentaplegic 1 (SMAD1)] interacts with the transcription factor SMAD1 and 
promotes the transcription of non-canonical bone morphogenetic protein (BMP) target genes 
(9). FAM83H mutations have been reported in both familial and spontaneous cases of 
amelogenesis imperfecta (AI), a genetic dental condition associated with soft enamel due to 
defective tooth mineralization  (10-12). No functions have yet been reported for FAM83C, 
FAM83E, or FAM83F. Despite the increasing evidence that FAM83 proteins are involved in 
diverse biological processes, the precise molecular and biochemical roles of the FAM83 
proteins, and in particular the DUF1669 domain that characterises them, remain undefined. 
By taking a comprehensive proteomic approach to uncover potential roles of the FAM83 family 
and the DUF1669 domain, we identified many unique interactors of each of the FAM83 proteins, 
consistent with the diverse sequence composition of these related proteins. Nevertheless, the a, 
a-like, d, and e isoforms of casein kinase 1 (CK1) were identified as interacting with each of the
FAM83 members, albeit with different affinities and specificities. CK1 enzymes in vertebrates
include the a, a-like, d, e, g1, g2, and g3 isoforms, all of which are serine-threonine protein
kinases. CK1 isoforms consist of a highly conserved N-terminal kinase domain that has little
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homology outside this family (13, 14). Within the CK1 family, there is greater overall sequence 
homology between the a and a-like isoforms, between the d and e isoforms, and between the 
g1, g2, and g3 isoforms (13, 14). CK1 isoforms play fundamental roles in many aspects of 
cellular homeostasis, including cell cycle progression (15), circadian rhythm (16-18), survival 
(19, 20), DNA damage repair (21), membrane trafficking, and integration of signalling processes 
(13-15). Increased catalytic activity of CK1 isoforms has been linked to cancer (14) and 
neurological pathologies (22). Due to their spontaneous in vitro kinase activity towards many 
substrates, CK1 isoforms are considered to be constitutively active kinases in cells (13). 
Consistent with the large number of cellular processes influenced by CK1 isoforms, they have 
been reported to localize to many subcellular compartments, including the plasma membrane, 
cytoplasm, nucleus, actin cytoskeleton, and mitotic spindle, and hundreds of putative substrates 
have been described (13, 15, 23). Although CK1 isoforms preferentially phosphorylate serine 
and threonine residues within the consensus sequence pS/pT-X-X-S/T, in many cases CK1 
isoforms phosphorylate residues outside the context of the consensus motif, such as the 
phosphorylation of b-catenin on Ser45 (13). In some cases, acidic residues can substitute for the 
phosphoserine or phosphothreonine residues within the consensus motif (13). All of these 
studies indicate that the localization, activity, and substrate specificity of CK1 are tightly 
regulated in cells. 
 
Interacting proteins that potentially control the subcellular localization, substrate accessibility, 
stability, or activity of CK1 isoforms remain elusive. Two scaffold proteins, the centrosomal and 
golgi N-kinase anchoring protein (CG-NAP, also known as AKAP450) and the DEAD-box RNA 
helicase DDX3, have been implicated in the centrosomal localization of CK1d during the cell 
cycle and in Wnt-dependent phosphorylation of Dishevelled (DVL) by CK1ε, respectively (24, 
25). The potential existence of CK1 scaffolds in cells is supported by an analogous role for the 
A-kinase anchoring proteins (AKAPs), which are established scaffolds that control the activity 
and substrate specificity of protein kinase A (PKA; also known as cAMP-dependent kinase) by 
interacting with PKA and tethering it to distinct subcellular compartments (26). 
 
Our data suggest that the DUF1669 domain of the FAM83 family mediates the interaction of 
these proteins with CK1 isoforms. FAM83 members localized to different subcellular 
compartments and co-localized in cells only with the CK1 isoforms with which they interacted in 
vitro. Mutations within the DUF1669 domain that abolish the interaction with CK1 interfered with 
the localization of both the FAM83 members themselves as well as their CK1 binding partners. 
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We hypothesise that FAM83 members, through their association with CK1 isoforms, restrict the 
function of CK1 enzymes in cells by directly controlling their subcellular localization, and 
perhaps their activity, stability, or substrate specificity. 
 
Results 
 
The FAM83 members interact with CK1 isoforms 
The FAM83 family of proteins is characterized by a conserved domain of unknown function, 
termed DUF1669, that is present at their N-termini, whereas the rest of the proteins vary in 
length and are not conserved between members (Fig. 1A; fig. S1). In order to investigate the 
roles of the FAM83 family of proteins, we generated transgenic human embryonic kidney HEK 
293 cell lines each stably expressing a single copy of a FAM83 gene under the control of a 
tetracycline (Tet)-inducible promoter. All 8 of the transgenically-expressed FAM83 proteins were 
tagged at the N-terminus with green fluorescent protein (GFP). In these cell lines, doxycycline 
treatment induced the expression of the respective FAM83 protein in a time-dependent manner, 
with detectable amounts observed as early as 30 min after doxycycline treatment (Fig. 1B). 
Similarly, we generated U2OS osteosarcoma cells stably integrated with a single copy of each 
FAM83 gene tagged at the C-terminus with green fluorescent protein (GFP). All FAM83 
proteins, except FAM83B, displayed robust expression following 24 h treatment with 
doxycycline (Fig. 1C). For both sets of cell lines (HEK 293 and U2OS), cells stably integrated 
with GFP alone under the Tet-inducible promoter were used as controls. 
 
Following induction with doxycycline, extracts from HEK 293 and U2OS cells expressing the 
GFP control and the FAM83 proteins tagged with GFP at either the N-terminus (HEK 293) or C-
terminus (U2OS) were subjected to GFP immunoprecipitation and separation of the 
immunoprecipitated proteins by SDS-PAGE (fig. S2, A and B). The gel sections including the 
entire lane for each sample were excised and digested with trypsin (fig. S2, A and B). The 
resulting peptides were identified using mass spectrometry. In addition to confirming the identity 
of the respective FAM83 proteins in each lane, we identified SMAD isoforms in GFP-FAM83G 
immunoprecipitates (2) and DYNLL1 and HMMR in GFP-FAM83D immunoprecipitates (7, 8) (fig 
S2, A and B), consistent with previously reported observations of these protein-protein 
interactions. Under these conditions, at least one or more of the a, a-like, d, and e isoforms of 
CK1 were identified as interactors for every FAM83 family member, regardless of the positioning 
of the GFP tag and the cell line in which the fusion protein was expressed (Fig. 2A). Analysis of 
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the top three precursor ion intensities of the individual CK1 isoforms bound to each GFP-FAM83 
protein from HEK 293 extracts revealed that although all FAM83 members interacted with CK1a 
and a-like, only FAM83A, FAM83B, FAM83E, and FAM83H interacted with CK1d and CK1e 
(Fig. 2A). Similar patterns in spectral intensities were observed for CK1a, CK1d, and CK1e 
bound to FAM83-GFP proteins from U2OS cell extracts, whereas CK1a-like was not detected in 
FAM83C, FAM83D, and FAM83H immunoprecipitations (Fig. 2A). Although we observed 
differences in spectral intensities for each CK1 isoform associated with different FAM83 
members, it is difficult to interpret these differences because the relative amount of FAM83 
protein in each lane was quite different as judged by the intensity of Instant blue stains (fig S2, A 
and B). 
 
To verify the interactions between FAM83 members and CK1 isoforms, GFP-FAM83A–H or 
control GFP immunoprecipitates from HEK 293 extracts were probed for co-precipitation of 
endogenous CK1a, d, and e isoforms. The relative amounts of FAM83 proteins in 
immunoprecipitates varied in that the amounts of FAM83B and FAM83D, both in extracts and 
immunoprecipitates, were lower as compared to other FAM83 members (Fig. 2B; fig. S3A). 
Under these conditions and in agreement with the mass spectrometry data above, all GFP-
FAM83 proteins interacted with CK1a, whereas GFP alone did not (Fig. 2B). We observed that 
FAM83B, FAM83E, FAM83G, and FAM83H appeared to interact more strongly with CK1a than 
did FAM83A, FAM83C, FAM83D, and FAM83F (Fig. 2B).  Endogenous CK1d and e were mainly 
detected in FAM83B, FAM83E, and FAM83H immunoprecipitates, although CK1e was also 
observed in FAM83A immunoprecipitates (Fig. 2B). In line with the proteomic data, endogenous 
SMAD1 co-precipitated with only FAM83G, whereas endogenous HMMR and DYNLL1 co-
precipitated exclusively with FAM83D (Fig. 2B). 
 
We next sought to verify endogenous interactions between some FAM83 members and the a 
and e isoforms of CK1. Given the absence of robust immunoprecipitating antibodies recognizing 
FAM83 members, we exploited CRISPR/Cas9 genome editing technology to introduce GFP-tag 
knock-ins at the FAM83B and FAM83G loci in HaCaT keratinocytes and U2OS cells 
respectively. GFP tags were thus inserted into the N-terminus of endogenous FAM83B and into 
the C-terminus of endogenous FAM83G. The disappearance of the endogenous FAM83B and 
FAM83G signals at the predicted molecular weights upon GFP-tag knock-ins and their 
concomitant appearance at higher molecular weights equivalent to the addition of GFP, in 
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combination with genomic DNA sequencing, confirmed the insertion of the GFP tag at the 
appropriate loci (fig. S3B). Whereas we detected endogenous CK1a in GFP immunoprecipitates 
from extracts of cells expressing GFP-FAM83B and from cells expressing FAM83G-GFP, we 
detected CK1e only in immunoprecipitates from cells expressing GFP-FAM83B (Fig. 2, C and 
D). We detected neither the a nor e isoform of CK1 in GFP immunoprecipitates from wild-type 
cells (Fig. 2, C and D). Furthermore, we observed endogenous FAM83G and FAM83H proteins 
in CK1a immunoprecipitates from U2OS cell extracts but not in pre-immune IgG control 
immunoprecipitates (Fig. 2E). The CK1 branch of the human protein kinase family also includes 
g1, g2, and g3 isoforms of CK1, tau-tubulin kinase (TTBK1), TTBK2, vaccinia-related kinase 1 
(VRK1), VRK2, and VRK3 (27). In U2OS cell extracts, under co-expression conditions in which 
FAM83G interacted with CK1a, we were unable to detect interactions between FAM83G and 
either TTBK2 or CK1g (fig. S4A). This, together with the proteomic data, suggests that FAM83 
members interact only with one or more of the a, a-like, d, and e isoforms of CK1 but not with 
CK1g1, CK1g2, CK1g3, or other members of the CK1 family. 
 
The DUF1669 domain is sufficient to mediate the interaction of FAM83 proteins with CK1 
Because all eight FAM83 family members contain the DUF1669 domain (Fig. 1A; fig S1), we 
postulated that this domain might mediate the observed interaction between FAM83 and CK1 
proteins. To map the minimal domain within FAM83 proteins that can interact with CK1 
isoforms, we co-expressed Myc-tagged FAM83G fragments with full-length hemagglutinin (HA)-
tagged CK1a in FAM83G-/- U2OS cells (28) and performed coimmunoprecipitation experiments 
(Fig. 3A). HA-CK1a immunoprecipitates only included those FAM83G fragments that contained 
residues 165-307 within the DUF1669 domain (Fig. 3A). We asked whether the interaction 
between the DUF1669 domain and CK1 was direct by performing an in vitro binding assay with 
purified recombinant proteins: a His-tagged form of residues 124–304 of FAM83A [6xHis-
FAM83A(124-304)] and the kinase domain of CK1e. Following precipitation of His-FAM83A 
(124-304) with nickel resin and its elution using imidazole, we observed both CK1e and FAM83A 
(124-304) in the eluate, suggesting a robust and direct interaction between the two (Fig. 3B). To 
probe the CK1 isoform–specific nature of the interactions of FAM83 members, we replaced the 
DUF1669 domain of FAM83G, which interacts only with CK1a, with that of FAM83H, which 
interacts with both CK1a and CK1e. We expressed this chimeric protein (DUF1669H-FAM83G) 
in HEK 293 cells and tested whether they interacted with CK1a and CK1e in cell extracts. The 
DUF1669H-FAM83G chimera interacted with both CK1a and CK1e, much like FAM83H (fig. S5), 
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suggesting that the DUF1669 domain of FAM83H is sufficient to confer selectivity for specific 
CK1 isoforms. 
 
A CK1 docking motif that includes the amino acid sequence F-X-X-X-F was identified in nuclear 
factor of activated T cells 1 (NFAT1), Period 1 (PER1), and PER2, and mutation of either 
phenylalanine residue abolished CK1 interactions with these proteins (29). One such F-X-X-X-F 
motif is conserved within the DUF1669 domain of the FAM83A–G proteins, and FAM83H has 
four such motifs (30) (fig. S1). To determine whether mutations within this conserved motif were 
sufficient to disrupt the CK1 interaction, we tested the ability of FLAG-tagged wild-type and 
various mutant forms of FAM83G (FAM83GF296A, FAM83GF300A, and FAM83GF296A,F300A) to 
interact with HA-CK1 when coexpressed in FAM83G-/- U2OS cells. Whereas wild-type FAM83G 
interacted robustly with CK1a, the FAM83GF296A and FAM83GF296A,F300A mutants did not (Fig. 
3C). Rather surprisingly, FAM83GF300A interacted with CK1a as robustly as did wild-type 
FAM83G (Fig. 3C), suggesting that the mode through which CK1 interacts with FAM83 proteins 
might differ from that through which it interacts with NFAT1, PER1, and PER2, which requires 
both phenylalanine residues (29). Consistent with this notion, mutational scanning of conserved 
residues within the 165–307 region of FAM83G uncovered another mutation, D262A, that also 
abolished the interaction with CK1a (31). 
 
Armed with the knowledge that the D262A and F296A mutations both abolish the interaction of 
FAM83G with CK1a, we asked whether equivalent mutations in other FAM83 members also 
abolished their association with CK1a and CK1e isoforms. We mutated the residues equivalent 
to FAM83G Asp262 and Phe296 in FAM83E (Asp243 and Phe277), FAM83F (Asp250and Phe284), and 
FAM83H (Asp236 and Phe270) to Ala. These substitutions are referred to as DA and FA, 
respectively. We individually expressed wild-type GFP-FAM83E–H, the DA mutants (GFP-
FAM83E–HDA), and the FA mutants (GFP-FAM83E–HFA) in U2OS cells and tested their ability to 
coimmunoprecipitate endogenous CK1a or CK1e isoforms. In comparison to wild-type 
FAM83E–H, both the DA and FA mutations attenuated the interaction of FAM83 proteins with 
CK1a and CK1e isoforms (Fig. 3D). These observations suggest that the interaction between 
the DUF1669 domain and CK1 isoforms may be mediated through a conserved structural motif 
surrounding the residues equivalent to Asp262 and Phe296 in FAM83G. Consistent with previous 
observations (Fig. 2, B to D), although FAM83E and FAM83H bound to both CK1a and CK1e, 
FAM83F and FAM83G bound only to CK1a (Fig. 3D). 
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FAM83 proteins and CK1a colocalize in cells 
Given the interaction between all of the FAM83 members and CK1a in cell extracts, we sought 
to investigate whether FAM83 proteins also interact with CK1a in cells. We coexpressed 
mCherry-CK1a and an N-terminally GFP-tagged FAM83 family member (GFP-FAM83) under 
the control of a Tet-inducible promoter in U2OS cells and evaluated the localization of both 
proteins by fluorescence microscopy. We performed this experiment with each FAM83 family 
member (GFP-FAM83A–H). Upon induction of GFP-FAM83 expression, we observed 
overlapping colocalization of every GFP-FAM83 member with mCherry-CK1a (Fig. 4), with each 
FAM83 protein exhibiting a distinct pattern of subcellular localization. Pan-cellular staining was 
observed for both GFP-FAM83A and GFP-FAM83B, along with additional perinuclear punctate 
structures for FAM83A and membrane punctate structures for FAM83B (Fig. 4). GFP-FAM83C 
displayed distinct fibrous patterns of fluorescence in the cytoplasm and in the vicinity of 
membrane ruffles, suggesting possible colocalization with cortical actin stress fibres (Fig. 4). 
GFP-FAM83D displayed cytoplasmic staining, with some punctate staining in the nucleus (Fig. 
4). FAM83D had previously been reported to localize to the spindle apparatus during mitosis (7, 
8). GFP-FAM83E exhibited cytoplasmic and strong perinuclear staining (Fig. 4). GFP-FAM83F 
localized to the plasma membrane, with some staining also observed in the cytoplasm and 
nucleus (Fig. 4). As reported previously (2), GFP-FAM83G localized mainly to the cytoplasm, 
but some nuclear staining was also noted (Fig. 4). GFP-FAM83H displayed primarily 
cytoplasmic, and few nuclear, punctate fluorescence patterns (Fig. 4), like the patterns 
described previously for FLAG-FAM83H overexpressed in HCT116 cells (11). In cells 
expressing both mCherry-CK1a and the GFP tag (not fused to a FAM83 protein), the GFP 
signal was predominantly nuclear and did not overlap with the mCherry signal, which was 
present throughout the cell (fig. S6). When expressed alone, mCherry-CK1a displayed a pan-
cellular staining pattern (fig. S6). These observations describe the subcellular localization 
profiles for all FAM83 members and demonstrate that each member colocalizes with CK1a. 
 
To confirm whether endogenous CK1a also displayed similar overlapping subcellular 
distribution with FAM83 members, we examined the subcellular localization pattern of 
endogenous CK1a in U2OS cells stably expressing GFP, GFP-FAM83B, GFP-FAM83F, or 
GFP-FAM83H. No overlapping fluorescence was detected between endogenous CK1a and 
GFP, which was employed as a negative control (Fig. 5). Overlapping plasma membrane and 
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perinuclear staining was observed for endogenous CK1a and GFP-FAM83B (Fig. 5). Likewise, 
strong overlapping plasma membrane staining was observed for endogenous CK1a and GFP-
FAM83F (Fig. 5). GFP-FAM83H and endogenous CK1a displayed overlapping staining in 
cytoplasmic and nuclear speckles (Fig. 5). Collectively these observations demonstrate that 
upon overexpression, each FAM83 protein is capable of relocating endogenous CK1a to the 
distinct subcellular compartments in which they reside. 
 
The association between FAM83 proteins and specific CK1 isoforms is selective in cells 
The above data demonstrated that all eight FAM83 members (A–H) interacted and colocalized 
with both overexpressed and endogenous CK1a and that FAM83A, FAM83B, FAM83E, and 
FAM83H also interacted with the CK1d and CK1e isoforms in cell extracts. To determine 
whether the specificity of FAM83 proteins for binding to a specific subset of CK1 isoforms 
applied to cells as well as to cell extracts, we compared the subcellular distribution of CK1a and 
CK1e with that of FAM83F, which interacted selectively with CK1a in cell extracts, and FAM83H, 
which interacted with both CK1a and CK1e in cell extracts. GFP-FAM83F or GFP-FAM83H was 
coexpressed in U2OS cells with either mCherry-CK1a or mCherry-CK1e. As observed earlier 
(Fig. 4 and 5), we found that both GFP-FAM83F and GFP-FAM83H displayed overlapping 
fluorescence with mCherry-CK1a, at the plasma membrane and in cytoplasmic speckles, 
respectively (Fig. 6A). In contrast, GFP-FAM83H, but not GFP-FAM83F, also colocalized with 
mCherry-CK1e at these sites (Fig. 6A). Next, we sought to verify whether the binding specificity 
of GFP-FAM83F and GFP-FAM83H extended to endogenous CK1a and CK1e. In wild-type 
U2OS cells, endogenous CK1a and CK1e both displayed pan-cellular distributions, with some 
speckle-like structures also visible in the cytoplasm (Fig. 6B). In U2OS cells expressing GFP-
FAM83F, we observed overlapping plasma membrane colocalization only with endogenous 
CK1a but not with CK1e (Fig. 6B). In contrast, in U2OS cells expressing GFP-FAM83H, we 
observed overlapping cytoplasmic and nuclear speckle staining patterns with both endogenous 
CK1a and CK1e (Fig. 6B). These data are consistent with our observations using 
overexpressed mCherry-CK1a and mCherry-CK1e (Fig. 6A). Collectively, these data 
recapitulate in cells the distinct sets of interactions that we observed between FAM83 members 
and CK1 isoforms from the proteomic data (Fig. 2A). 
 
Association with CK1 determines the subcellular localization of FAM83C 
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We next asked whether the interaction between CK1 and FAM83 proteins was important for 
their subcellular localizations. For this purpose, we chose GFP-FAM83C because of its distinct 
cortical fibre-like subcellular localization pattern (Fig. 4). First, we confirmed in cell extracts that 
only wild-type GFP-FAM83C coimmunoprecipitated HA-tagged CK1a and that the GFP-
FAM83CD259A and GFP-FAM83CF293A mutants and control GFP did not (Fig. 7A). Next, we co-
transfected U2OS cells with mCherry-CK1a and wild-type GFP-FAM83C, GFP-FAM83CD259A, or 
GFP-FAM83CF293A and examined their subcellular localization by fluorescence microscopy. 
Whereas GFP-FAM83C and mCherry-CK1a fluorescence colocalized along fibrous structures 
(Fig. 4 and 7B), GFP-FAM83CD259A and GFP-FAM83CF293A were predominantly found in the 
cytoplasm, in slightly distorted fibrous fluorescence patterns that did not overlap with mCherry-
CK1a fluorescence (Fig. 7B). When it was expressed alone or with the FAM83CD259A and GFP-
FAM83CF293A mutants, mCherry-CK1a was found in a diffuse cytoplasmic pattern, but adopted a 
fibrous appearance in the cytoplasm when it was co-expressed with wild-type FAM83C (Fig. 
7B). These observations suggest that the interaction between FAM83C and CK1a determines 
the subcellular localization of both proteins.  
 
FAM83H co-localizes with and contributes to the subcellular localization of endogenous 
CK1a and CK1e isoforms 
We have shown that FAM83H displays a distinct punctate fluorescence pattern when 
overexpressed in U2OS cells (Fig. 4 to 6). We generated FAM83H-/- U2OS cells using 
CRISPR/Cas9 genome editing technology and asked whether endogenous CK1a colocalized 
with GFP-FAM83H that was transgenically expressed in these cells. In FAM83H-/- cells, CK1a 
was primarily cytoplasmic with few perinuclear puncta. When GFP-FAM83H was expressed 
transgenically, both GFP-FAM83H and endogenous CK1a adopted a pan-cellular punctate 
pattern (Fig. 8A). Although the majority of GFP-FAM83H puncta overlapped with endogenous 
CK1a staining, suggesting robust co-localization, the presence of some non-overlapping GFP-
FAM83H and CK1a puncta suggest that FAM83H and CK1a may exist in complexes with other 
proteins (Fig. 8A). When the CK1-interaction deficient mutants, GFP-FAM83HD236A and GFP-
FAM83HF270A, were expressed in FAM83H-/- U2OS cells, they displayed cytoplasmic, non-
punctate fluorescence that did not overlap with endogenous CK1a (Fig. 8A). The intensity of 
CK1a punctate staining in FAM83H-/- cells and in FAM83H-/- cells expressing CK1-binding–
deficient mutant forms of FAM83H was lower compared to that seen in cells expressing wild-
type GFP-FAM83H (Fig. 8A), suggesting that the interaction with FAM83H determines the 
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localization of CK1a to the punctate structures. Next, we quantified the co-localization 
correlation between CK1a and wild-type GFP-FAM83H, GFP-FAM83HD236A or GFP-
FAM83HF270A. The localization of CK1a positively correlated with that of wild-type GFP-FAM83H 
(Pearson correlation coefficient 0.7523), whereas it did not correlate with the GFP-FAM83HD236A 
(0.001504) or GFP-FAM83HF270A (0.001504) mutants (Fig. 8B). Rescue of FAM83H-/- U2OS 
cells with wild-type or mutant GFP-FAM83H constructs was confirmed by Western blotting and 
suggested that the abundance of FAM83H in these cells was substantially higher than the 
amount of endogenous FAM83H in wild-type U2OS cells (Fig. 8C). In FAM83H-/- U2OS cells, 
endogenous CK1e displayed similar immunostaining patterns to CK1a (fig. S7A) and displayed 
significant co-localization correlation with wild-type GFP-FAM83H but not the GFP-FAM83HD236A 
or GFP-FAM83HF270A mutants (fig. S7B). Overlapping fluorescence observed between CK1α 
immunostaining and mCherry-CK1α fluorescence (fig. S8A), and between CK1ε immunostaining 
and mCherry-CK1ε fluorescence (fig. S8B), confirmed the selectivity of the antibodies 
recognizing CK1α and CK1ε, respectively, for immunofluorescence applications. 
 
The intrinsic catalytic activity of CK1 is not affected by or required for the association of 
CK1 with FAM83 proteins 
Because they associate with CK1 isoforms, it is possible that the FAM83 members could be 
substrates of CK1 or affect the intrinsic kinase activity of CK1. We tested whether CK1a 
phosphorylated FAM83 proteins in vitro using purified proteins. Whereas recombinant FAM83B, 
FAM83C, and FAM83G were robustly phosphorylated by CK1a, the other FAM83 members 
were phosphorylated poorly (Fig. 9A). The precise CK1 phosphorylation sites on most FAM83 
proteins have not been mapped, and whether these phosphorylation events occur in cells and 
their potential functional consequences have not been investigated. The low activity of CK1a 
toward some of the FAM83 substrates in our in vitro kinase assay could reflect the poor purity of 
some of the recombinant FAM83 proteins (Fig. 9A) or their lack of any putative priming 
phosphorylation. The optimal CK1 phosphorylation motif is pS-x-x-S/T (13) . We previously 
showed that CK1a phosphorylates FAM83G only on Ser614 in vitro, but this phosphorylation 
event does not appear to affect function of FAM83G in Xenopus laevis embryos, which requires 
its association with CK1 (31).  
 
In order to test whether the intrinsic catalytic activity of CK1a was affected by its association 
with FAM83, we performed an in vitro CK1a kinase assay with increasing concentrations of an 
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optimized CK1 peptide substrate (CK1tide), and evaluated whether the addition of equimolar 
amounts of either wild-type FAM83G or a CK1-interaction–deficient FAM83G mutant (F296A, 
F300A) altered the rate of CK1a catalysis or its Michaelis constant (Km) toward the CK1tide 
substrate. The intrinsic CK1a catalytic activity against CK1tide was not significantly altered by 
the addition of either wild-type or the F296A, F300A mutant FAM83G at all CK1tide 
concentrations tested, suggesting that FAM83G does not affect the intrinsic kinase kinetics of 
CK1a (Fig. 9B). We also assessed whether the kinase activity of CK1a was required for its 
association with FAM83 members. For this, we transiently co-expressed GFP-FAM83E, GFP-
FAM83F, GFP-FAM83G, or GFP-FAM83H with either mCherry-tagged wild-type CK1a or the 
catalytically inactive mutant CK1aN141A (32) in U2OS cells and performed co-
immunoprecipitation assays. Equal amounts of both wild-type CK1a and the CK1aN141A mutant 
were detected in immunoprecipitates of FAM83E–H (Fig. 9C), suggesting that CK1 kinase 
activity is dispensable for the FAM83:CK1 interaction. 
 
 
Discussion 
 
The various CK1 isoforms are known to control a myriad of cellular processes, yet how their 
activities are regulated in cells remains poorly defined. In this report, we identified the FAM83 
family of proteins as interactors of the a, a-like, d, and e isoforms of CK1 in mammalian cells. 
This interaction was mediated through the conserved DUF1669 domain of FAM83 proteins, with 
different family members exhibiting distinct affinities and isoform-selectivity for CK1. FAM83 
proteins displayed unique subcellular distribution patterns that overlapped with the specific CK1 
isoforms with which they associate. Point mutations within the DUF1669 domains of FAM83 
proteins that abolished CK1 association disrupted not only the co-localization of FAM83 
members with specific CK1 isoforms in cells, but also the subcellular localization of the 
respective FAM83 members themselves. Our findings imply that the DUF1669 domains of 
FAM83 proteins anchor CK1 a, a-like, d, and e isoforms in specific subcellular compartments 
and potentially mediate their association with substrates, perhaps similar to the A-kinase 
anchoring proteins (AKAPs) that streamline signal transduction by bringing protein kinase A into 
close proximity of its substrates (26).  
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Unlike AKAPs, which bind to the regulatory domain of PKA, the DUF1669 domain of FAM83 
proteins appeared to associate directly with the kinase domain of CK1 isoforms and did so 
independently of CK1 catalytic activity. There are many other examples of the crucial roles that 
scaffolding and anchoring proteins play in organizing and streamlining signal transduction in 
cells (33-36). TPX2 (targeting protein for Xklp2) is a scaffold protein that recruits Aurora kinase 
A to the mitotic spindle and activates the kinase allosterically (37). However, FAM83G did not 
influence the intrinsic catalytic activity of CK1a in vitro. Because some FAM83 members were 
substrates for CK1 isoforms in vitro, future work will be required to establish whether there are 
roles for some FAM83 proteins as substrates of CK1 in cells. The DUF1669 domain contains a 
pseudo-PLD-like catalytic motif, yet FAM83 proteins do not exhibit phospholipase activity (5). 
Hence, there could very well be features within the DUF1669 domain that still harbour certain 
pseudo-PLD roles, such as binding to specific phospholipids, that might affect binding to CK1. 
Future work will aim to explain the specificity and affinity with which FAM83 members bind 
different CK1 isoforms. 
 
Precisely how FAM83 members impact the diverse functions of CK1 isoforms in cells is largely 
unclear, but we are beginning to uncover some of these roles. We have established that 
FAM83G is a critical mediator of Wnt signalling in human cells and Xenopus embryos (31). 
Crucially, we showed that unlike wild-type FAM83G, two mutants incapable of interacting with 
CK1a are unable to activate Wnt signalling or induce axis duplication in Xenopus embryos (31). 
Similarly, a recent report suggested that FAM83H and the DNA binding protein SON recruit CK1 
to nuclear speckles (38). From our proteomic data, it is evident that each FAM83 member 
interacts with unique proteins in addition to the CK1 isoforms. Future investigations will establish 
whether FAM83 proteins individually recruit distinct sets of substrates to specific CK1 isoforms. 
Furthermore, by controlling the localization of CK1 isoforms, different FAM83 proteins might be 
primed to streamline diverse signal transduction processes downstream of CK1. Future efforts 
will aim to establish precisely which CK1 substrates are affected by individual FAM83 members. 
Additionally, global phosphoproteomic approaches in cells devoid of individual FAM83 members 
generated by genome editing techniques will identify potential substrate maps for CK1 isoforms. 
 
Given the involvement of CK1 isoforms in a wide range of cellular processes, it is no surprise 
that their misregulation has been linked to cancers and neurological disorders (15, 22). The 
pleiotropic nature of CK1 function in regulating many cellular processes, combined with poor 
understanding of its regulation, has limited the exploration of CK1 for therapeutics. Nonetheless, 
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several potent inhibitors of individual CK1 isoforms have been developed, including CKI-7, 
IC261, D4476, PF-670462 and PF-4800567, although all suffer from selectivity issues, with off-
target effects related to their inhibition of other CK1 isoforms and protein kinases (39-43). Our 
findings clearly place the FAM83 proteins at the helm of CK1 regulation in cells. Therefore, 
understanding the molecular bases for FAM83:CK1 associations may provide us with unique 
opportunities to target and disrupt this association with small molecules, which could prove to be 
useful in targeting specific CK1 isoforms in specific cellular compartments. 
 
In light of our data that clearly demonstrates that the DUF1669 domain is responsible for 
facilitating the interaction between FAM83 members and CK1 isoforms, we propose that the 
DUF1669 domain be renamed polypeptide anchor of CK1 (PACK1) domain. Co-crystallization 
of the PACK1 domain with CK1 isoforms will potentially reveal the determinants of CK1 
interaction specificity and affinity for each FAM83 member.     
 
Materials and Methods 
 
Plasmids 
Recombinant DNA procedures were performed using standard protocols as described 
previously (2, 44). Human FAM83A-H and CK1 wild-type genes or appropriate mutants were 
sub-cloned into pcDNA5-FRT/TO vectors with a Green Fluorescence Protein (GFP) tag at either 
the N- or the C-terminus, or an mCherry tag at the N-terminus. All constructs are available to 
request from the MRC-PPU reagents webpage (http://mrcppureagents.dundee.ac.uk) and the 
unique identifier (DU) numbers indicated above provide direct links to the cloning strategy and 
sequence information. The following constructs were generated: pcDNA5-FRT/TO GFP-
FAM83A (DU44235), pcDNA5-FRT/TO GFP-FAM83B (DU44236), pcDNA5-FRT/TO GFP-
FAM83C (DU42473), pcDNA5-FRT/TO GFP-FAM83D (DU42446), pcDNA5-FRT/TO GFP-
FAM83E (DU44237), pcDNA5-FRT/TO GFP-FAM83F (DU44238), pcDNA5-FRT/TO GFP-
FAM83G (DU33272), pcDNA5-FRT/TO GFP-FAM83H (DU44239), pcDNA5-FRT/TO GFP-
FAM83C (D259A) (DU28479), pcDNA5-FRT/TO GFP-FAM83C (F293A) (DU28480), pcDNA5-
FRT/TO GFP-FAM83E (D243A) (DU28481), pcDNA5-FRT/TO GFP-FAM83E (F277A) 
(DU28482), pcDNA5-FRT/TO GFP-FAM83F (D250A) (DU28268), pcDNA5-FRT/TO GFP-
FAM83F (F284A) (DU28488), pcDNA5-FRT/TO GFP-FAM83G (D262A) (DU28476), pcDNA5-
FRT/TO GFP-FAM83G (F296A) (DU28477), pcDNA5-FRT/TO GFP-FAM83H (D236A) 
(DU28428), pcDNA5-FRT/TO GFP-FAM83H (F270A) (DU28487), pcDNA5-FRT/TO mCherry-
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CK1α (DU28407), pcDNA5-FRT/TO mCherry-CK1α (N141A) (DU28839), pcDNA5-FRT/TO 
GFP-FAM83H(M1-L284)-FAM83G(S311-P823) (DU28683), pcDNA5-FRT/TO GFP-
FAM83G(M1-V310)-FAM83H(V285-K1179) (DU28688), pcDNA5-FRT/TO FAM83A-GFP 
(DU42864), pcDNA5-FRT/TO FAM83B-GFP (DU42833), pcDNA5-FRT/TO FAM83C-GFP 
(DU42825), pcDNA5-FRT/TO FAM83D-GFP (DU42835), pcDNA5-FRT/TO FAM83E-GFP 
(DU42826), pcDNA5-FRT/TO FAM83F-GFP (DU42832), pcDNA5-FRT/TO FAM83G-GFP 
(DU42816), pcDNA5-FRT/TO FAM83H-GFP (DU42865), pcDNA5-FRT/TO GFP only 
(DU41455), pcDNA5-FRT/TO GFP-FAM83H (F274A) (DU28658), pcDNA5-FRT/TO GFP-
FAM83H (F270, 274A) (DU28182), pcDNA5-FRT/TO FLAG-FAM83G (DU33274), pcDNA5-
FRT/TO FLAG-FAM83G (F296A) (DU28024), pcDNA5-FRT/TO FLAG-FAM83G (F296A, 
F300A) (DU28026), pcDNA5-FRT/TO FLAG-FAM83G (F300A) (DU28025), pCS2+ HA-CK1α 
(DU28216), pCMV5-FLAG TTBK2 (DU19028), pCMV-FLAG-CK1γ (DU5580), pCS2+ HA CK1δ 
(DU28189), pcDNA5-FRT/TO mcherry-CK1ε (DU28406). Myc-xFAM83G (Xenopus laevis 
FAM83G) constructs have been described previously (28). For CRISPR/Cas9 gene editing, 
pBABED P U6 FAM83H KO sense gRNA (DU52010), pX335-CAS9-D10A FAM83H KO 
antisense gRNA (DU52026), pBABED P U6 FAM83G KI sense gRNA (DU48528), pX335-Cas9-
D10A FAM83G KI antisense gRNA (DU48529), pEX-K4 FAM83G Cter GFP donor (DU48585), 
pBABED P U6 FAM83B KI sense gRNA (DU54494), pX335-Cas9-D10A FAM83B KI antisense 
gRNA (DU54504), and pEX-K4 FAM83B Nter GFP donor (DU54547) were generated. 
Constructs were sequence-verified by the DNA Sequencing Service, University of Dundee 
(http://www.dnaseq.co.uk). For plasmid amplification, 1 μl of the plasmid was transformed into 
10 μl of E. coli DH5α competent bacteria (Invitrogen) on ice, incubated at 42°C for 45 s, then on 
ice for 2 min, before plating on LB-agar medium plate containing 100 μg/ml ampicillin. Plates 
were inverted and incubated for 16 h at 37°C. A single colony was picked and used to inoculate 
250 ml of LB medium containing 100 μg/ml ampicillin, and cultures were grown for 18 h at 37°C 
in a shaker (Infors HT). Plasmid DNA was purified using a Qiagen midi-prep kit as per the 
manufacturer’s instructions. The isolated DNA yield was subsequently analysed using a 
Nanodrop 1000 spectrophotometer (Thermo Scientific).  
 
Antibodies 
Rabbit anti-GAPDH (cat.: 2118, 1:5000), anti-CK1δ (cat.: 12417S, 1:1000), and anti-CK1ε (cat.: 
12448, 1:1000) were from Cell Signalling Technology (CST). Rat anti-GFP for detection of 
endogenous GFP tags was from Chromotek (cat.: 3H9, 1:1000). Anti-CK1α (cat.: A301-991A, 
1:1000 for immunoblotting, 5 µg antibody/mg of cell extract protein for immunoprecipitation) and 
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anti-FAM83H (cat.: A304-327A, 1:1000) were from Bethyl. Anti-DYNLL1 (EP1660Y, 1:1000) and 
anti-FAM83B (cat.: 153829, 1:1000) were from Abcam. Anti-HMMR (cat.: ABC323, 1:1000) was 
from Millipore. Sheep anti-PAWS1/FAM83G (S876C, 3rd bleed, 1:1000), anti-FAM83H (SA273, 
4th bleed, 1:1000), anti-GFP (S268B, 2nd bleed, 1:1000) and anti-SMAD1 (S618C, 3rd bleed, 
1:1000) were generated by the Division of Signal Transduction Therapy (DSTT), University of 
Dundee (2, 45). anti-FLAG M2-Peroxidase (HRP) (cat.: A8592, 1:2000) and anti-c-Myc-HRP 
(cat.: A5598, 1:2000) were from Sigma and Anti-HA-HRP (cat.: 11667475001, 1:2000) was from 
Roche. For HRP-coupled secondary antibodies, goat anti-rabbit-IgG (cat.: 7074, 1:2500) was 
from CST, rabbit anti-sheep-IgG (cat.: 31480, 1:5000), goat anti-rat IgG (cat.: 62-9520, 1:5000) 
and goat anti-mouse-IgG (cat.: 31430, 1:5000) were from Thermo Fisher. For 
Immunofluorescence, anti-CK1-alpha (C-19 Santa Cruz Biotechnology, 1:100) and anti-CK1-
epsilon (HPA026288 Sigma, 1:500) were used. For signal amplification, AlexaFluor-594 donkey 
anti-goat IgG (H+L) (A11058 Life Technologies, 1:300), AlexaFluor-594 goat anti-rabbit IgG 
(H+L) (A11012 Invitrogen™ Molecular Probes™, 1:500) and AlexaFluor-488 donkey anti-rabbit 
IgG (H+L) (A21206, Life Technologies, 1:500) were employed. 
 
Cell Culture 
Human osteosarcoma U2OS, human embryonic kidney HEK 293, human keratinocyte HaCaT, 
Flp-In T-Rex U2OS and HEK 293, and retroviral production HEK 293(FT) cell lines were grown 
in Dulbecco’s Modified Eagles Medium (DMEM; Gibco) containing 10% (v/v) Foetal Bovine 
Serum (FBS; Hyclone), penicillin (100 U/ml; Lonza), streptomycin (0.1 mg/ml; Lonza) and L-
glutamine (2 mM; Lonza), and cultured at 37°C, 5% CO2 in a humidified incubator. For transient 
transfections, cells were transfected for 24 h with 2 μg (per 10 cm-dish), or 500 ng (per 6-well 
dish with coverslips) cDNA, in serum free OptiMem (Gibco) with the transfection reagent 
polyethylenimine (PEI) as described previously (44). Where applicable, Tet-inducible expression 
was achieved by adding doxycycline (20 ng/ml) for up to 24 h prior to cell lysis as indicated. 
 
Generation of Stable Flp-In T-Rex Cell Lines 
The Flp-In T-Rex U2OS or HEK 293 cells were transfected with the N- or C-terminal GFP-
tagged FAM83A-H or GFP alone packaged into a pcDNA5-FRT/TO vector, together with the Flp 
recombinase pOG44 (Invitrogen) in a ratio of 1 μg : 9 μg as described previously (2, 46). Briefly, 
plasmids were diluted in 1 ml OptiMem (Gibco), 20 μl of 1 mg/ml polyethylenimine (PEI) was 
added, the mix vortexed and left at room temperature for 15 min and added dropwise to 10 cm 
dish of target cells in 10 ml complete medium. 24 h post-transfection, cells were selected in 
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media containing hygromycin (50 μg/ml) and blasticidin (15 µg/ml). Resistant cells were grown 
up to confluency, tested for doxycycline-induced expression of GFP-tagged proteins and used in 
subsequent experiments. 
 
Generation of FAM83GGFP/GFP and GFP/GFPFAM83B knock-in cells using CRISPR/Cas9 
U2OS and HaCaT cells were transfected with vectors encoding a pair of guide RNAs (pBABED-
Puro-sgRNA1 and pX335-Cas9-D10A-sgRNA2) targeting around the stop codon of FAM83G 
and the start codon of FAM83B (1 μg each), along with the respective donor plasmids carrying 
the GFP knockin insert and flanking homology arms (~500 bases) (3 μg each). 16 h post-
transfection, cells were selected in puromycin (2 µg/ml) for 2 days. The transfection process 
was repeated one more time. GFP-positive cells were isolated by fluorescence-activated cell 
sorting (FACS) and single GFP-positive cell clones were plated on individual wells of two 96-
well plates, pre-coated with 1% (w/v) gelatin as described previously (45). Viable clones were 
expanded, and the integration of GFP at the target locus was confirmed by Western blotting and 
genomic sequencing of the targeted locus. The DU identifier numbers for the plasmids listed 
above link to the sequences for gRNA and donors with homology arms for each target. 
 
Generation of FAM83G-/- and FAM83H-/- cells using CRISPR/Cas9 
CRISPR/Cas9 mediated deletion of FAM83G in U2OS cells was performed using Cas9 and a 
single gRNA targeting approach to delete exon 2 of the RefSeq gene for FAM83G 
(NM_001039999.2). Vectors containing the Cas9 and FAM83G targeting gRNA 
(ggaccgctccatcccgcagctgg) were transfected into 1x106 U2OS cells followed by selection with 2 
ug/ml puromycin. Single cell sorting was used to isolate clone candidates, which were screened 
with Western blotting and confirmed by genomic sequencing. For FAM83H, U2OS cells were 
transfected with vectors encoding a pair of guide RNAs (pBABED-Puro-sgRNA1 and pX335-
Cas9-D10A-sgRNA2) targeting the second exon of FAM83H (1 μg each). 16 h post-transfection, 
cells were selected in puromycin (2 µg/ml) for 2 days. The transfection process was repeated 
one more time. Cells were isolated by single-cell sorting and isolated clones were plated on 
individual wells of two 96-well plates, pre-coated with 1% (w/v) gelatin as described previously 
(45). Viable clones were expanded and successful knockout of FAM83H was confirmed by 
Western blotting and genomic sequencing of the targeted locus. The DU identifier numbers for 
the plasmids listed above link the sequences for gRNA for each target. 
 
Cell Lysis and Immunoprecipitation 
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Cells were washed twice in ice-cold phosphate-buffered saline (PBS), before scraping on ice in 
lysis buffer (50 mM Tris-HCl pH 7.5, 0.27 M sucrose, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 
1 mM sodium orthovanadate, 10 mM sodium β-glycerophosphate, 50 mM sodium fluoride, 5 
mM sodium pyrophosphate, and 1% Nonidet P40 substitute), supplemented with 1X protease 
inhibitor cocktail (Roche). Cell extracts were either cleared and processed immediately, or snap 
frozen in liquid nitrogen, before storing at -80°C. Protein concentrations were determined in a 
96-well format using Bradford protein assay reagent (Pierce). 
 
For immunoprecipitation, clarified extracts were diluted in lysis buffer to 1-5 mg/ml. Input 
aliquots were taken, and lysates were incubated overnight at 4°C with protein G-sepharose 
beads coupled to the antibody of interest, on a rotating wheel. For anti-GFP 
immunoprecipitations, GFP-TRAP A beads (Chromotek) were used; for anti-FLAG 
immunoprecipitations, anti-FLAG M2 affinity agarose gel (Sigma) were used. Following the 
incubation period, beads were pelleted and flow-through extracts collected. Beads were washed 
once in lysis buffer supplemented with 250 mM NaCl and 2-3 times in lysis buffer. Beads were 
eluted in 1X SDS sample buffer, at 95°C for 5 min. 
 
For immunoprecipitations for mass-spectrometry, cells were lysed in DSP crosslinking lysis 
buffer (40 mM HEPES pH 7.4, 120 mM NaCl, 1 mM EDTA, 10 mM sodium pyrophosphate, 50 
mM sodium fluoride, 1.5 mM sodium orthovanadate, 1% (v/v) triton, 1X protease inhibitor 
cocktail (Roche), and 2.5 mg/ml DSP as described previously (2). Following lysis, lysates were 
incubated for 30 mins at 4°C, before quenching the crosslinking reaction by adding 1 M Tris-HCl 
pH 7.4 in a ratio of 1:4 and incubating at 4°C for a further 30 min. Lysates were clarified by 
centrifugation at 15000 rpm for 20 min and filtered through 0.45 μM filters (BioRad). Extracts 
were pre-cleared by incubating with Protein-G sepharose beads for 1 h at 4°C on a rotating 
wheel. Pre-cleared lysates were quantified using the Bradford method, and extracts incubated 
with GFP-TRAP A beads (Chromotek) for 4 h at 4°C on a rotating wheel. Input and post-
immunoprecipitation extract aliquots were taken for control blots. Beads were washed twice in 
lysis buffer supplemented with 250 mM NaCl, and three times in lysis buffer. 1X SDS sample 
buffer containing 0.1 M DTT was added to the beads (~50% slurry), and samples incubated at 
37°C for 1 h. Samples were then boiled at 95°C for 5 min and eluted through SpinX columns 
(Corning). 
 
Mass Spectrometry 
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The expression of GFP-tagged FAM83 proteins in stable Flp-In T-Rex HEK 293 and U2OS cells 
was induced with 20 ng/ml doxycycline for 24 h prior to lysis. Proteins were affinity purified from 
clarified extracts by GFP-TRAP A beads (ChromoTek) as described above. Purified proteins 
were resolved by 4-12% gradient SDS-PAGE, the gels were stained with Instant blue and gel 
slices covering each lane were excised and trypsin digested. The peptides were subjected to 
mass spectrometric analysis performed by LC-MS-MS on a Linear ion trap-orbitrap hybrid mass 
spectrometer (Orbitrap-VelosPro, Thermo) coupled to a U3000 RSLC Hplc (Thermo). Peptides 
were trapped on a nanoViper Trap column, 2 cm x 100 µm C18 5 µm 100 Å (Thermo, 164564) 
then separated on a 15 cm Thermo EasySpray column (ES800) equilibrated with a flow of 300 
nl/min of 3% Solvent B. [Solvent A: 2% Acetonitrile, 0.1% formic acid, 3% DMSO in H2O; 
Solvent B: 80% acetonitrile, 0.08% formic acid, 3% DMSO in H2O]. The elution gradient was as 
follows; Time (min):Solvent B (%); 0:3, 5:3, 45:35, 47:99, 52:99, 55:3, 60:3. Data were acquired 
in the data-dependent mode, automatically switching between MS and MS-MS acquisition. Full 
scan spectra (m/z 400-1600) were acquired in the orbitrap with resolution R = 60,000 at m/z 400 
(after accumulation to an FTMS Full AGC Target; 1,000,000; FTMS MSn AGC Target; 50,000). 
The 20 most intense ions, above a specified minimum signal threshold (2,000), based upon a 
low resolution (R=15,000) preview of the survey scan, were fragmented by collision induced 
dissociation and recorded in the linear ion trap (Full AGC Target; 30,000. MSn AGC Target; 
5,000). Data files were analysed by Proteome Discoverer 2.0 (www.ThermoScientific.com), 
using Mascot 2.4.1 (www.matrixscience.com), and searching the SwissProt Human database. 
Scaffold Q/Q+S V4.4.7 (www.ProteomeSoftware.com) was also used to examine the Mascot 
result files. Allowance was made for the following fixed, Carbamidomethyl (C), and variable 
modifications, Oxidation (M), Dioxidation (M). Error tolerances were 10 ppm for MS1 and 0.6 Da 
for MS2. Scaffold Q/Q+S V4.3 (U2OS) or V4.4.6 (HEK 293) (www.ProteomeSoftware.com) was 
used to further analyse the data and obtain values for the Top 3 precursor ion intensities of each 
protein. 
 
SDS-PAGE and Western Blotting 
Reduced protein extracts (10–20 μg protein) or immunoprecipitates were resolved on either 8% 
(v/v) SDS-PAGE gels, or 4-12% NuPAGE bis-tris precast gradient gels (Invitrogen) by 
electrophoresis. Separated proteins were subsequently transferred onto polyvinylidene fluoride 
(PVDF) membranes (Millipore), before membranes were blocked in 5% (w/v) non-fat milk 
powder (Marvel) in TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.2% (v/v) Tween-20) and 
incubated overnight at 4°C in 5% milk TBS-T or 5% bovine serum albumin (BSA) TBS-T with 
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the appropriate primary antibody. Membranes were then washed 3 X 10 min with TBS-T before 
incubating with HRP-conjugated secondary antibodies in 5% milk TBS-T for 1 h at room 
temperature. Membranes were then washed 3 X 10 min with TBS-T before detection with 
enhanced chemiluminescence reagent (Millipore) and exposure to medical-grade X-ray films 
(Konica Minolta), as described previously (2, 47, 48).   
 
Fluorescence microscopy  
Cells were plated on glass coverslips and treated/transfected as described above. Cells were 
washed twice in PBS, before being fixed either with methanol at -20°C for 2 min or 4% (w/v) 
paraformaldehyde (PFA) in 200 mM HEPES pH 7.4 for 20 min at RT. Cells fixed in methanol 
were washed three times in ice cold PBS after fixation, then blocked in 3% BSA/PBS + 0.01% 
Tween 20 on ice for 30 min. Cells fixed in PFA were washed twice with DMEM/10 mM HEPES 
followed by incubation in DMEM/10 mM HEPES for 10 min at RT. Cells fixed in PFA were 
washed once in PBS and permeabilised for 3 min in 1.5 ml 0.2% NP40. Cells were then washed 
twice in PBS containing 1-3% (w/v) BSA, followed by incubation in PBS/BSA for 15 min. Where 
appropriate, coverslips were then incubated with primary antibody in PBS/BSA (typically at 1:50-
1:500 dilution as stated) at 30-37°C for 1-1.5 h. Cells were washed for a minimum of 3 X 10 min 
in PBS/BSA (PFA-fixed cells) or 3 X 5 min in PBS (methanol-fixed cells) on shaker. Coverslips 
were incubated with secondary Alexa-Fluor conjugated antibody in PBS/BSA (1:300-500 
dilution) and DAPI (1:500) for 30 to 60 min at RT in the dark. Coverslips were then washed for 3 
X 10 min in PBS/BSA (PFA-fixed cells) or 3 X 5 min in PBS (methanol-fixed cells), and mounted 
on glass microscopy slides using either ProLong® Gold anti-fade reagent with DAPI (Life 
Technologies) (if DAPI staining was not performed previously), or mounted using 
VECTASHIELD mounting solution (Vector Labs). Coverslips were sealed with clear nail varnish 
and left to dry overnight before imaging on either a Nikon TiS inverted microscope, or a 
DeltaVision Imaging Systems (GE Healthcare). Images were processed using either NIS 
Elements (Nikon) and Adobe Photoshop, or softWoRx (GE Healthcare) and Omero (49). 
 
Colocalization was assessed using the Pearson’s correlation coefficient (PCC) as a measure of 
intensity correlation between the two channels. As explained by Adler and Parmryd (50), PCC is 
sensitive to the inclusion of background pixels. We therefore excluded background pixels by 
auto-thresholding each channel in the cytoplasmic region of interest using Otsu’s method (51). 
Thresholding and PCC calculation were implemented in an ImageJ macro developed by G. Ball 
(Dundee) and is included as a Supplementary File (File S1). 
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In vitro kinase assays 
25 µl reactions were set up using 200 ng of kinase (GST-CK1α), 2 µg of substrate (GST-
FAM83A, C, D, E, F, or H, MBP-tagged FAM83B, or GST-FAM83G-6XHis in a buffer containing 
50 mM Tris pH 7.5, 0.1 mM EGTA, 10 mM Magnesium acetate, 2 mM DTT and 0.1 mM [γ32P]-
ATP (~500 cpm/pmol). Assays were performed at 30°C for 30 min and stopped by addition of 9 
μl of 4xSDS sample buffer with 5% β-mercaptoethanol and heating at 95°C for 5 min. The 
samples were resolved by SDS-PAGE and the gels were stained with Instant blue (Expedeon) 
and dried. Radioactivity was analysed by autoradiography. For peptide-based kinase assays, 
reactions were set up and performed as described previously (52), using an optimised CK1 
peptide substrate (CK1tide (KRRRALS*VASLPGL), where S* indicates phosphoserine). Assays 
were performed in triplicates. 
 
Protein expression and purification 
The DUF1669 domain of FAM83A (a.a. 122-304) and the kinase domain of human CK1ε (a.a. 
1-294) were expressed separately in E. coli strain BL21(DE3) R3-pRARE2 using the pNIC28-
Bsa4 vector, which encodes for a N-terminal hexahistidine (6XHis) tag and TEV cleavage site. 
Cultures were grown at 37°C in LB medium supplemented with 50 μg/mL kanamycin and 34 
μg/mL chloramphenicol to an OD of 0.6, before expression at 18°C overnight by induction with 
0.4 mM isopropyl 1-thio-β-D-galactopyranoside. Cells were harvested by centrifugation at 5000 
g and pellets resuspended in binding buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 
5 mM imidazole) supplemented with Calbiochem protease inhibitor set III. Cells were lysed by 
sonication before clarification of the lysate by centrifugation in a JA 25.50 rotor at 36,000 g. His-
tagged proteins were immobilized on Ni-sepharose and bound proteins were eluted using step 
gradients of imidazole (50-250 mM). CK1ε protein was cleaved with TEV protease overnight at 
4°C and both 6xHis-FAM83A and CK1ε were purified further by size exclusion chromatography 
using an S75 HiLoad 16/60 Superdex column equilibrated in buffer containing 50 mM HEPES 
pH 7.5, 300 mM NaCl, and 0.5 mM TCEP. Proteins were concentrated by centrifugal 
ultrafiltration using a 3 kDa molecular weight cut-off concentrator. Protein concentrations were 
determined by measuring absorbance at 280 nm. Protein purity of >95% was confirmed by 
SDS-PAGE and construct identities and tag cleavage were verified by mass spectrometry. 
 
All other recombinant proteins used in the in vitro kinase assays were purified by the Division of 
Signal Transduction Therapy (DSTT; University of Dundee) and the identities of the expressed 
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proteins verified by mass spectrometry. Each protein has a unique identification number to 
request from the MRC-PPU Reagents website (http://mrcppureagents.dundee.ac.uk) as follows: 
GST-CK1α (DU329),GST-FAM83A (DU24611), GST-FAM83C (DU28269), GST-FAM83D 
(DU28270), GST-FAM83E (DU28271), GST-FAM83F (DU28272), GST-FAM83H (DU28403) 
and GST-FAM83G (F296A, F300A) (DU28049). Briefly, the proteins were expressed in 
BL21(DE3) E. coli as described above and affinity purified using GSH-sepharose, Amylose-
sepharose or Nickel-agarose columns as appropriate. 
 
In vitro binding assay 
For the in vitro binding assay, all proteins and Ni-sepharose were equilibrated in binding buffer 
(50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 5 mM imidazole) prior to use. 300 μg 
6xHis-FAM83A (aa122-304) was immobilised onto 200 μl Ni-sepharose and washed before 
addition of 100 μg CK1ε. The Ni-sepharose was then washed with binding buffer and the flow 
through collected. Two 1 ml wash steps were performed using binding buffer before bound 
proteins were eluted with 1 ml binding buffer supplemented with 250 mM Imidazole. Fractions 
were run on a SDS-PAGE gel alongside the original protein solutions for molecular weight 
reference. 
 
Statistical Analysis 
For kinase assays, GraphPad (Prism) was used to generate plots and analyse data by two-way 
ANOVA and Tukey test to determine statistical significance, from 3 independent experiments, 
each containing 3 replicates. A p-value of <0.05 was deemed significant. For co-localization 
studies, GraphPad (Prism) was used to generate boxplots and analyze data by one-way 
ANOVA and Dunnett’s multiple comparison test to determine statistical significance. A p-value 
of <0.05 was deemed significant. 
 
Supplementary Materials 
Fig. S1: Sequence alignment of the DUF1669 domain of the FAM83 proteins. 
Fig. S2: Coomassie images of GFP-TRAP immunoprecipitations of FAM83A-H proteins used to 
identify interacting partners by mass spectrometry 
Fig. S3: Immunoblots of controls for Figure 2 
Fig. S4: FAM83G interacts with CK1α, but not CK1γ or TTBK1 
Fig. S5: CK1-specificity switch with DUF1669 chimera 
Fig. S6: Fluorescence images of GFP and mCherry-CK1a controls 
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Fig. S7: FAM83H co-localizes with and contributes to the subcellular localization of endogenous 
CK1ε 
Fig. S8: Validation of CK1a and CK1e antibodies for immunofluorescence applications 
File S1: Supplemental ImageJ Macro for quantification of co-localization in cells. 
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Figure Legends 
 
Fig. 1: Generation of HEK 293 and U2OS cells for tetracycline-inducible expression of 
FAM83 proteins. A. Schematic representation of the human FAM83 family of proteins and the 
conserved domain of unknown function, DUF1669, that characterises them. B. A single copy of 
each FAM83 gene (A–H) tagged with GFP at the N-terminus was stably inserted downstream of 
a tetracycline-inducible promoter in HEK 293 cells. Cells were treated with doxycycline and 
lysed at the indicated times after treatment. Extracts were resolved by SDS-PAGE and 
subjected to immunoblotting (IB) for GFP. ERK1 and ERK2 (ERK1/2) and GAPDH are loading 
controls. This blot is representative of 2 independent experiments.  C. A single copy of each 
FAM83 gene (A–H) tagged with GFP at the C-terminus was stably inserted downstream of a 
tetracycline-inducible promoter in U2OS cells. Extracts of doxycycline-induced cells were 
immunoblotted for GFP and the loading control GAPDH. FAM83B is not included on the blot 
because we were unable to detect FAM83B-GFP expression in U2OS cells. This blot is 
representative of 2 independent experiments. 
 
Fig. 2: FAM83 proteins interact with CK1 isoforms. A. Mass fingerprinting of protein 
interactors of FAM83A–H proteins tagged N-terminally (HEK 293 cells) or C-terminally (U2OS 
cells) with GFP (fig. S2, A and B) identified one or more CK1 isoforms. These tables show the 
values for the top 3 precursor ion intensities of the indicated CK1 isoforms pulled down with 
each GFP-FAM83 protein (A–H) expressed in HEK 293 cells and each FAM83-GFP protein (A–
H) expressed in U2OS cells. GFP expressed in each cell line was a negative control. Scaffold 
Q/Q+S V4.4.6 was used for analysis of the LC-MS/MS data from HEK 293 cells, and scaffold 
V4.3 was used for analysis of the LC-MS-MS data from U2OS cells. FAM83B-GFP did not 
express in U2OS cells. B. GFP Immunoprecipitates (IP) of GFP control or GFP-FAM83A–H 
proteins expressed in HEK 293 cells were immunoblotted (IB) with antibodies recognizing the 
indicated CK1 isoforms and other proteins known to interact with FAM83 family proteins. Short 
Exp., short exposure; Long Exp., long exposure. C. Extracts of wild-type (WT) or GFP-FAM83B 
knockin (GFP/GFPFAM83B) HaCaT cells were immunoprecipitated with GFP-TRAP A beads and 
immunoblotted to detect the indicated CK1 isoforms. GAPDH was used as a loading control. FT, 
flow through. D. As in C., except that proteins were immunoprecipitated from WT and FAM83G-
GFP knockin (FAM83GGFP/GFP) U2OS cell extracts. E. U2OS extracts were immunoprecipitated 
using either pre-immune IgG or an antibody recognizing CK1a coupled to Protein-G sepharose 
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beads and immunoblotted with antibodies recognizing the indicated FAM83 proteins and 
GAPDH. All blots are representative of 3 independent experiments. 
 
Fig. 3:  The DUF1669 domain is sufficient to mediate the interaction of FAM83 proteins 
with CK1. A. The indicated fragments of Myc-tagged Xenopus laevis FAM83G (Myc-xFAM83G) 
were co-expressed with HA-CK1a in FAM83G-/- U2OS cells, and then cell extracts or HA 
immunoprecipitates were subjected to immunoblotting (IB) with antibodies recognizing Myc or 
HA as indicated. This blot is representative of 3 independent experiments. B. A His-tagged 
fragment of FAM83A (amino acids122-304), which contains the DUF1669 and PLD-like 
domains, was mixed with recombinant CK1ε kinase domain (amino acids 1-294) in vitro. His-
FAM83A(122-304) was then pulled down using Ni-sepharose (Ni2+) resin, which was washed 
twice before elution. The input, unbound flow-through (FT), wash solutions (W1 and W2), and 
eluate (E) were analysed by SDS-PAGE and stained with Coomassie blue. This gel is 
representative of 3 independent experiments. C. Empty Flag vector (ctrl) or the indicated FLAG-
FAM83G mutant and wild-type (WT) proteins were overexpressed in FAM83G-/- U2OS cells. 
Cell extracts (input) and FLAG immunoprecipitates (IP) were subjected to immunoblotting for 
FLAG, CK1a, or GAPDH as indicated. This blot is representative of 3 independent experiments. 
D. WT and Phe®Ala (FA) and Asp®Ala (DA) mutant forms of GFP-FAM83E–H were transiently 
expressed in U2OS cells, immunoprecipitated (IP) from cell extracts with a GFP-specific 
antibody, and immunoblotted for GFP, CK1α, and CK1ε as indicated. This blot is representative 
of 3 independent experiments. 
 
Fig. 4: FAM83 proteins and CK1a colocalize in cells. U2OS cells stably integrated with Tet-
inducible expression of GFP-FAM83A–H were transfected with mCherry-CK1a. Cells were 
processed for fluorescence microscopy following 24h of doxycycline treatment. DNA was 
stained with DAPI. Images from one field of view representative of 3 independent experiments 
are shown. The number of cells that displayed staining patterns identical to the representative 
image were documented for each experiment: GFP-FAM83A (n=50); GFP-FAM83B (n=31); 
GFP-FAM83C (n=37); GFP-FAM83D (n=32); GFP-FAM83E (n=55); GFP-FAM83F (n=44); 
GFP-FAM83G (n=43); GFP-FAM83H (n=32). Fluorescence images for GFP-alone and 
mCherry-CK1a alone expressing cells are included in fig. S6. Scale bar, 20 µM. 
 
Fig. 5: FAM83 proteins colocalize with endogenous CK1a in cells.  
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U2OS cells stably integrated with Tet-inducible expression of GFP, GFP-FAM83B, GFP-
FAM83F, or GFP-FAM83H were treated with doxycycline for 16 h prior to processing cells for 
fluorescence microscopy to detect GFP and endogenous CK1a (anti- CK1a). DNA was stained 
with DAPI. Images from one field of view representative of three independent experiments are 
shown. The number of cells displaying staining patterns identical to the representative image 
were documented for each experiment: GFP-FAM83B (n=56); GFP-FAM83F (n=60); GFP-
FAM83H (n=48); GFP only (n=38); no transgene (n=82). Scale bars, 20 µm. 
 
Fig. 6: The association between FAM83 proteins and specific CK1 isoforms is selective in 
cells. A. U2OS cells stably integrated with Tet-inducible expression of GFP-FAM83F or GFP-
FAM83H were transfected with either mCherry-CK1a (a) or mCherry-CK1e (e). GFP-FAM83F 
and GFP-FAM83H expression was induced with doxycycline for 24 h prior to processing cells 
for fluorescence microscopy. DNA was stained with DAPI. Images from one field of view 
representative of three independent experiments are included. The number of cells that 
displayed staining patterns identical to the representative image were documented for each 
experiment: GFP-FAM83F + mCherry-CK1a (n=44); GFP-FAM83F + mCherry-CK1e (n=40); 
GFP-FAM83H + mcherry-CK1a (n=32); GFP-FAM83H + mCherry-CK1e (n=40). Scale bar, 20 
µm. B. U2OS cells stably integrated with Tet-inducible expression of GFP-FAM83F or GFP-
FAM83H were induced with doxycycline for 16 h prior to processing cells for fluorescence 
microscopy with CK1a (a) or CK1e (e) antibodies. Untransfected cells stained with CK1a or 
CK1e antibodies were used as negative controls. Images from one field of view representative 
of three independent experiments are shown. The number of cells that displayed staining 
patterns identical to the representative image were documented for each experiment: GFP-
FAM83F with CK1a (n=60); GFP-FAM83F with CK1e (n=43); GFP-FAM83H with CK1a (n=48); 
GFP-FAM83H with CK1e (n=35); no transgene with CK1a (n=82); no transgene with CK1e 
(n=27).  Scale bars, 20 µm. 
 
Fig. 7: Association with CK1 determines the subcellular localization of FAM83C. A. U2OS 
cells were cotransfected with plasmids encoding either GFP, GFP-FAM83C (WT), GFP-
FAM83C(F293A) (FA), or GFP-FAM83C(D259A) (DA) plus a plasmid encoding HA-CK1a. 
Untransfected (UT) cells and cells transfected only with HA-CK1a were included as controls. 
Cell extracts (Input) or GFP-TRAP A Immunoprecipitates (IP) were immunoblotted (IB) with 
antibodies recognizing GFP and CK1a. a-Tubulin was used as a loading control. This blot is 
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representative of 3 independent experiments. B. U2OS cells were transfected with plasmids 
encoding GFP-FAM83C, GFP-FAM83C(F293A), or GFP-FAM83C(D259A), together with 
mCherry-CK1a. Cells expressing GFP-FAM83C or mCherry-CK1a alone are negative controls. 
Cells were processed 24 h after transfection for fluorescence microscopy. DNA was stained with 
DAPI. Images from one field of view representative of three independent experiments are 
shown. The number of cells which displayed staining patterns identical to the representative 
image were documented for each experiment: GFP-FAM83C only (n=46); GFP-FAM83C + 
mCherry-CK1a (n=44); GFP-FAM83C (F293A) + mCherry-CK1a (n=41); GFP-FAM83C 
(D259A) + mCherry-CK1a (n=43); mCherry-CK1a only (n=45). Scale bar, 20 µm. 
 
Fig. 8: FAM83H colocalizes with and contributes to the subcellular localization of 
endogenous CK1a. A. FAM83H-/- U2OS cells were transfected with plasmids encoding either 
GFP-FAM83H, GFP-FAM83H (D236A), or GFP-FAM83H (F270A). Untransfected knockout 
(FAM83H-/-) cells were used as controls. Cells were processed for fluorescence microscopy with 
antibody recognizing CK1a. DNA was stained with DAPI. Images from one field of view 
representative of 3 independent experiments are included. Scale bar, 10 µm. B. The boxplot 
shows the range, mean, and lower and upper quartiles of the Pearson’s correlation coefficients 
of GFP-FAM83H and endogenous CK1a intensities within above-background pixels in the 
cytoplasm. C. GFP-FAM83H constructs were transfected into FAM83H-/- U2OS cells, and 
extracts were immunoblotted (IB) with the indicated antibodies. Untransfected wild-type (WT) 
cells were used as controls. This blot is representative of three independent experiments. 
 
Fig. 9: The intrinsic catalytic activity of CK1 is not affected by or required for the 
association of CK1 with FAM83 proteins. A. An in vitro kinase assay was performed in the 
presence of [γ32P]-ATP with recombinant GST-CK1α plus one of the following recombinant 
FAM83 fusion proteins: GST-FAM83A (A), MBP-FAM83B (B), GST-FAM83C (C), GST-FAM83D 
(D), GST-FAM83E (E), GST-FAM83F (F), GST-FAM83G-6His (G), or GST-FAM83H (H). After 
the reactions were stopped, samples were resolved by SDS-PAGE. The gel was stained with 
Instant blue, dried, and subjected to 32P autoradiography for the indicated times. Instant blue–
stained gel and autoradiograph representative of 3 independent experiments are shown. B. An 
in vitro kinase assay was set up with recombinant GST-CK1α, and either recombinant GST-
FAM83G-6His or the GST-FAM83G (F296A, F300A) double mutant in the presence of 
increasing amounts of the optimized CK1 peptide substrate CK1tide. GST-CK1α, without 
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FAM83G addition, was used as a control. Data points represent the average from three 
independent experiments, each including three replicates. Error bars, SEM. C. U2OS cells were 
transiently co-transfected with GFP-FAM83E, GFP-FAM83F, GFP-FAM83G, or GFP-FAM83H 
and either WT CK1α or a catalytically inactive (kinase dead, KD) form of CK1α. After 24 h cell 
extracts (Input) were immunoprecipitated (IP) with GFP-TRAP A beads and immunoblotted (IB) 
with the indicated antibodies. This blot is representative of 3 independent experiments. GAPDH 
is a loading control.  
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Figure S1. Sequence alignment of the DUF1669 domain of the FAM83 proteins.  
Full sequence alignment of the DUF1669 domain indicating the putative pseudo-PLD catalytic motif, 
the location of predicted CK1-interaction FXXXF motifs (F in yellow), and the location of two 
residues essential for CK1-interaction (asterisks).  
 
  
 2 
Figure S2. Coomassie images of GFP-TRAP immunoprecipitations of FAM83A-H proteins 
used to identify interacting partners by mass spectrometry.  
(A) Extracts from doxycycline-treated (24 h) HEK 293 cells expressing N-terminally GFP-tagged 
FAM83A–H or GFP alone under the control of a Tet-inducible promoter were subjected to GFP trap 
immunoprecipitation and resolved by SDS-PAGE. The gels were Coomassie stained and imaged. 
The boxed regions in each lane represent the approximate excisions made in order to perform in-gel 
trypsin digestion and process the samples for protein identification by mass spectrometry. n=1. (B) 
As in A, except that C-terminally GFP-tagged FAM83A, FAM83C–H or GFP alone were expressed 
in U2OS cells, n=1.  
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Figure S3. Immunoblots of controls for Figure 2.  
(A) Cell extracts (Input) and flow-through following GFP immunoprecipitation were resolved by 
SDS-PAGE and immunoblotted with GFP antibodies. Short and long exposure images are shown. 
This blot is representative of 3 independent experiments. (B) Endogenous FAM83B and FAM83G 
genes were modified using CRISPR/Cas9 genome editing to insert GFP tags at the N terminus 
(GFP/GFPFAM83B) or C terminus (FAM83GGFP/GFP) of the gene. Cell extracts (Input) were resolved 
by SDS-PAGE and subjected to immunoblotting (IB) using the indicated antibodies. Cell extracts 
from unmodified cell lines (FAM83GWT/WT) are included. GAPDH is a loading control. This blot is 
representative of 3 independent experiments. 
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Figure S4. FAM83G interacts with CK1α, but not CK1γ or TTBK1.  
(A) The indicated FLAG- or HA-tagged CK1 isoforms and the related kinase TTBK2 were co-
expressed with FAM83G-GFP in U2OS cells. Cell extracts and GFP immunoprecipitations (IP) were 
resolved by SDS-PAGE and subjected to immunoblotting using the indicated antibodies. This blot 
is representative of 2 independent experiments. (B) Schematic highlighting the similarity of the 
kinase domains of various kinases of the CK1 kinase family. The percentage amino acid identity 
within the kinase domains of each kinase to that of CK1a kinase domain (aa 10-302) is indicated. 
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Figure S5. CK1-specificity switch with DUF1669 chimera.  
The DUF1669 domain of FAM83G, which interacts with CK1a only, was replaced with the 
DUF1669 domain of GFP-FAM83H, which interacts with both CK1a and CK1e. U20S cells were 
transfected with a construct encoding this chimeric protein (GFP-DUFH-FAM83G) or a construct 
encoding wild-type GFP-FAM83G or GFP-FAM83H. Cell extracts (Input) and GFP 
immunoprecipitations (IP) were resolved by SDS-PAGE and subjected to immunoblotting using 
the indicated antibodies. This blot is representative of 3 independent experiments. 
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Figure S6. Fluorescence images of GFP and mCherry-CK1a controls.  
U2OS cells stably integrated with Tet-inducible expression of GFP were transfected with mCherry-
CK1a. Wild-type U2OS cells were transfected with mCherry-CK1a as a negative control. GFP 
expression was induced with doxycycline for 24 h prior to processing cells for fluorescence 
microscopy. DNA was stained with DAPI. Representative images from one field of view from 3 
independent experiments are shown.  
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Figure S7. FAM83H co-localizes with and contributes to the subcellular localization of 
endogenous CK1ε.  
(A) FAM83H-/- U2OS cells were transfected with vectors encoding GFP-FAM83H, GFP-FAM83H 
(D236A), or GFP-FAM83H (F270A). Untransfected cells are included as a control. Cells were 
processed for fluorescence microscopy with an antibody recognizing CK1ε. DNA was stained with 
DAPI. Representative images from one field of view from 3 independent experiments are shown. 
Scale bar, 10 µm. (B) The boxplot shows the range, mean, and lower and upper quartiles of the 
Pearson’s correlation coefficients of GFP-FAM83H and endogenous CK1ε intensities within above-
background pixels in the cytoplasm.  
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Figure S8. Validation of antibodies recognizing CK1a and CK1e for immunofluorescence 
applications.  
(A) U2OS cells were transfected with mCherry-CK1a. Cells were processed for fluorescence 
microscopy with the CK1a antibody. DNA was stained with DAPI. Representative low and high 
exposure (exp.) images from one field of view from 1 experiment are included. (B) As in A, except 
that U2OS cells were transfected with mCherry-CK1e and stained with the CK1e antibody. 
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File S1.  Supplemental ImageJ macro for quantification of protein co-localization in 
cells. 
This macro is provided as a separate .txt file. 
 
 
 
